Tesamorelin

Details:

Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
 
Tesamorelin (also known as Egrifta) is a synthetic form which is used in the treatment of HIV-associated lipodystrophy.
 
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes
changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. 

Storage: Tesamorelin peptides although stable at room temperature for 3 months, should be stored desiccated below -18° C. 
Upon reconstitution of the peptide it should be stored at 4° C between 2-21 days and for future use below -18° C.

Quick Details:
CAS  140703-51-1

Purity: 99%
Specification: 2mg/vial
Appearance: White Lyophilized Powder
Place of Origin: China
Standard: USP
Certification: SGS
Method of Analysis: HPLC
Storage: Lyophilized peptides although stable at room temperature for 3 months, should be stored desiccated below -18° C. Upon reconstitution of the peptide it should be stored at 4° C between 2-21 days and for future use below -18° C.

Fat Loss and the Tesamorelin Peptide
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).

Application:
Tesamorelin, (formerly known as TH9507), is a type of peptide called a growth hormone-releasing factor (GHRF). GHRF causes growth hormone to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy. Tesamorelin (formerly known as TH9507) is a synthetic growth hormone-releasing factor that stimulates the pituitary gland in the brain to secrete growth hormone; this indirect approach appears to maintain more stable, natural levels, like CJC-1295 DAC,. Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorlein is discontinued (depending upon the individual). Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in NON-HIV-Infected individuals.

Studied as a way to reduce excess deep belly fat, the synthetic human growth hormone releasing factor called tesamorelin (Egrifta) was approved by the FDA in November 2010 and has been available since January 2011. Results from a 52-week study of 816 people showed 18% less deep belly fat in those on tesamorelin than those taking placebo

Do NOT use tesamorelin if:
you are allergic to any ingredient in tesamorelin or to mannitol
you are pregnant
you have cancer, an underactive pituitary gland, or a pituitary gland tumor
you have had your pituitary gland removed, pituitary gland surgery, radiation treatment of the head, or a head injury

Contact your doctor or health care provider right away if any of these apply to you.